Sandoz Group AG (SDZNY)
Market Cap | 18.88B |
Revenue (ttm) | 10.11B |
Net Income (ttm) | -8.00M |
Shares Out | n/a |
EPS (ttm) | -0.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | 0.38 (0.87%) |
Ex-Dividend Date | May 3, 2024 |
Volume | 7,950 |
Open | 44.20 |
Previous Close | 43.88 |
Day's Range | 43.86 - 44.36 |
52-Week Range | 25.71 - 44.98 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 5, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
In 2023, SDZNY's revenue was $9.98 billion, an increase of 7.23% compared to the previous year's $9.31 billion. Earnings were $77.00 million, a decrease of -90.92%.
Financial StatementsNews
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
![](https://cdn.snapi.dev/images/v1/h/b/press10-2582994.jpg)
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalm...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Sandoz Group Non-GAAP EPS of $1.12, revenue of $5B
Sandoz Group Non-GAAP EPS of $1.12, revenue of $5B
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG 2024 Q2 - Results - Earnings Call Presentation
Sandoz Group AG 2024 Q2 - Results - Earnings Call Presentation
![](https://image.cnbcfm.com/api/v1/image/108017993-17231220511723122048-35732521324-1080pnbcnews.jpg?v=1723122050&w=1920&h=1080)
Won't see major development in weight loss indication drugs in EU or U.S. until 2030, Sandoz CEO says
Richard Saynor, CEO of Sandoz, discusses the firm's half-year results and shares his outlook for innovation in the weight loss drug market.
Generic weight-loss drugs? They’re coming — eventually, executive says
Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.
![](https://cdn.snapi.dev/images/v1/q/z/press3-2576159.jpg)
Sandoz reports second-quarter sales and half-year 2024 results
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net s...
![](https://cdn.snapi.dev/images/v1/n/u/press14-2543973.jpg)
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, ...
![](https://cdn.snapi.dev/images/v1/b/4/press11-2504067.jpg)
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is appr...
![](https://cdn.snapi.dev/images/v1/g/l/press6-2442756.jpg)
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines ...
![](https://cdn.snapi.dev/images/v1/o/9/press3-2413786.jpg)
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in U...
![](https://cdn.snapi.dev/images/v1/d/a/press1-2399117.jpg)
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and ...
![](https://cdn.snapi.dev/images/v1/x/e/biotech33-2398869.jpg)
Sandoz reaches agreement with Amgen over patent dispute
Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.
![](https://cdn.snapi.dev/images/v1/j/1/press18-2398835.jpg)
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears pa...
![](https://cdn.snapi.dev/images/v1/c/6/press4-2382322.jpg)
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming...
![](https://cdn.snapi.dev/images/v1/x/v/press2-2335218.jpg)
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 m...
![](https://cdn.snapi.dev/images/v1/t/y/press12-2321436.jpg)
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in U...
![](https://cdn.snapi.dev/images/v1/e/r/press9-2309257.jpg)
Sandoz receives FDA approval for first and only denosumab biosimilars
MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosumab) F...